Structure Therapeutics (GPCR) News Today $21.94 +0.46 (+2.14%) Closing price 04:00 PM EasternExtended Trading$21.76 -0.19 (-0.84%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Structure Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Structure Therapeutics (GPCR) Projected to Announce Earnings on ThursdayOctober 29 at 7:25 AM | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low - Here's WhyOctober 28 at 12:40 PM | marketbeat.comStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Now Rated "Moderate Buy" by Wall Street AnalystsOctober 21, 2026 | americanbankingnews.comStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Price Target of $110.91 According to BrokeragesOctober 21, 2026 | marketbeat.comStructure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2026October 19, 2026 | globenewswire.comStructure Therapeutics (GPCR) Stock May Be A Bargain Given Its Asset BaseOctober 17, 2026 | finance.yahoo.comStructure Therapeutics (NASDAQ:GPCR) Hits New 52-Week Low - Should You Sell?October 14, 2026 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Hits New 12-Month Low - Time to Sell?October 8, 2026 | marketbeat.comWall Street Zen Downgrades Structure Therapeutics (NASDAQ:GPCR) to Strong SellOctober 3, 2026 | marketbeat.comStructure Therapeutics (NASDAQ:GPCR) Stock Price Down 6.1% - Here's What HappenedSeptember 29, 2026 | marketbeat.comGPCR Share News TodaySeptember 24, 2026 | uk.investing.comStructure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In FocusSeptember 22, 2026 | finance.yahoo.comStructure Therapeutics Inc ADR (GPCR)September 19, 2026 | za.investing.comStructure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comStructure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?September 10, 2026 | insidermonkey.comStructure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - SlideshowSeptember 9, 2026 | seekingalpha.comStructure Therapeutics: The Amylin Data Changes The MathSeptember 9, 2026 | seekingalpha.comStructure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management TranscriptSeptember 8, 2026 | seekingalpha.comStructure Therapeutics Reports Positive Data From Oral Amylin And GLP-1 ProgramsSeptember 8, 2026 | rttnews.comStructure Therapeutics Reports Up to 16.2% Weight Loss in Aleniglipron TrialSeptember 8, 2026 | finance.yahoo.comStructure Therapeutics falls after trial data for lead obesity drugsSeptember 8, 2026 | seekingalpha.comStructure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight ManagementSeptember 8, 2026 | markets.businessinsider.comStructure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight ManagementSeptember 8, 2026 | globenewswire.comStructure Therapeutics to Participate in Upcoming Healthcare Investor ConferencesSeptember 3, 2026 | globenewswire.comSepterna: GPCR Programs May Be Experimental, But I'm Holding For The Long TermAugust 28, 2026 | seekingalpha.comJefferies Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)August 12, 2026 | theglobeandmail.comStructure Therapeutics Reports Second Quarter 2026 Financial Results and Recent HighlightsAugust 7, 2026 | finance.yahoo.comA small-cap contender looking to challenge the weight-loss drug giantsJuly 24, 2026 | msn.comStructure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy NowJuly 3, 2026 | finance.yahoo.comH.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)June 17, 2026 | finance.yahoo.comStructure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)June 11, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)June 9, 2026 | theglobeandmail.comStructure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comStructure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for AleniglipronJune 8, 2026 | finance.yahoo.comDoes Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?June 7, 2026 | finance.yahoo.comStructure's experimental obesity pill shows no signs of liver injuryJune 5, 2026 | reuters.comStructure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for ObesityJune 5, 2026 | globenewswire.comStructure Therapeutics Announces Participation in Upcoming Investor ConferencesMay 26, 2026 | globenewswire.comIf Viking Therapeutics Is Acquired, Here's Who WinsMay 26, 2026 | 247wallst.comThis Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 MillionMay 24, 2026 | fool.comThis Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 MillionMay 17, 2026 | fool.comStructure Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026 | globenewswire.comWhy Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA PlansMay 3, 2026 | finance.yahoo.comHere is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look atMay 1, 2026 | finance.yahoo.comCanaccord Genuity initiates coverage of Structure Therapeutics Inc. - Depositary Receipt (GPCR) with buy recommendationApril 28, 2026 | msn.comStructure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific SessionsApril 27, 2026 | globenewswire.comStructure Therapeutics, Inc. Sponsored ADRApril 18, 2026 | edition.cnn.com3 Ways to Invest in the Growing GLP-1 Weight Loss Market (GPCR)GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.April 17, 2026 | marketbeat.comStructure Therapeutics Appoints Matthew Lang as Chief Operating OfficerApril 17, 2026 | theglobeandmail.comStructure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General CounselApril 14, 2026 | globenewswire.com Structure Therapeutics Media Mentions By Week Structure Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GPCR News Sentiment▼0.440.68▲Average Healthcare News Sentiment Structure Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GPCR Articles This Week▼34▲GPCR Articles Average Week Structure Therapeutics Trends on MarketBeatThis week vs. last weekSearches3Page Views2,224-12% Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Belite Bio News Veradermics News Definium Therapeutics News Indivior News Arcutis Biotherapeutics News Liquidia News Organon & Co. News Tarsus Pharmaceuticals News Regencell Bioscience News MBX Biosciences News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Structure Therapeutics dated 10/29/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
